Arena (ARNA) Confirms FDA Approval of BELVIQ
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Arena (ARNA) Partner Eisai May Also Have Promising Weight-Loss Pill in the Works
October 16, 2012 9:29 AM EDTArena Pharmaceutical (Nasdaq: ARNA) shares are notably higher Tuesday amid news that its partner in BELVIQ might have an weight-loss drug winner on its hands as well.
According to Bloomberg, citing a study published in the Archives of Internal... More
